Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up
The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.
Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.
Price: 1.31, Change: +0.04, Percent Change: +3.07
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.
close
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
State Street's Q1 Earnings, Revenue Increase
MT Newswires - 21 minutes ago
-
Puerto Rico power restored to 41.5% of customers after island-wide blackout
Reuters - 23 minutes ago
-
Tilray to Seek Approval for Reverse Stock Split at Stockholders' Meeting
MT Newswires - 24 minutes ago
-
Regions Financial's first-quarter profit rises on strong wealth management income
Reuters - 24 minutes ago
-
Market Chatter: BlackRock, MSC in Talks to Separate Panama Ports From Hutchison Deal
MT Newswires - 27 minutes ago
-
UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation
MT Newswires - 27 minutes ago
-
Ford Motor to Recall up to 150,000 Vehicles
MT Newswires - 30 minutes ago
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
